Terry Heiman-Patterson, MD, Director of the Temple MDA/ALS Center of Hope, offered insight to Neurology Today about the news that the 48-week randomized, placebo-controlled phase 3 PHOENIX trial on Relyvrio did not meet its primary and secondary endpoints. The clinical trial had enrolled 664 adults with amyotrophic lateral sclerosis, or ALS.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH